Sonnet BioTherapeutics Holdings Inc
SONN
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.43M
Close$
$-0.42
133.4% downside
Current Fair Value
133.4% downsideOvervalued by 133.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.43 Million |
|---|---|
| Enterprise Value | $3.36 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.95 |
| Beta | 1.47 |
| Outstanding Shares | 4,081,296 |
Return
| Return on Equity | -149.36% |
|---|---|
| Return on Assets | -108.25% |
| Return on Invested Capital | -147.16% |
Valuation & Multiples
| P/E Ratio | -0.32 |
|---|---|
| PEG | -0.39 |
| Price to Sales | - |
| Price to Book Ratio | 0.63 |
| Enterprise Value to Revenue | 3.36 |
| Enterprise Value to EBIT | -0.21 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 610.28%▲ 605.73% |
|---|---|
| Total Invested | $110.83M▲ 49443.28% |
| Investors Holding | 29▲ 20.00% |
ESG Score
No data
About Sonnet BioTherapeutics Holdings Inc
8 employees
CEO: Pankaj Mohan Founded in 2011, Sonnet Biotherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB™ (Fully Human Albumin Binding), th...